FIELD: medicine.
SUBSTANCE: method involves introducing Viferon immunomodulator at a dose of 2 mln IU per day rectally, as the first treatment stage. Then, antibacterial and antisecretory preparations are introduced in usual way.
EFFECT: enhanced effectiveness of treatment; potentiated eradication activity of therapy.
2 dwg
Title | Year | Author | Number |
---|---|---|---|
DIAGNOSTIC TECHNIQUE FOR DEGREE OF ACTIVITY OF ANTRAL HELICOBACTER-ASSOCIATED GASTRITIS IN PATIENTS WITH BRONCHIAL ASTHMA | 2009 |
|
RU2394499C1 |
METHOD OF PREDICTING RISK OF DEVELOPMENT OF DESTRUCTIVE CHANGES OF GASTRODUODENTAL ZONE MUCOUS TUNIC | 2008 |
|
RU2391915C1 |
METHOD FOR EVALUATING THE STATE OF GASTROINTESTINAL BARRIER IN PATIENTS AFTER RADICAL DUODENOPLASTY | 2006 |
|
RU2306869C1 |
METHOD OF HELICOBACTER PYLORI ERADICATION IN PERIODONTAL TISSUES | 2009 |
|
RU2394617C1 |
METHOD FOR INDIVIDUALIZATION OF ANTI-HELICOBACTER THERAPY IN CHILDREN IN CASE OF FUNCTIONAL DYSPEPSIA | 2005 |
|
RU2275912C1 |
TREATMENT OF INFLAMMATORY GASTROINTESTINAL DISEASED ASSOCIATED WITH HELICOBACTER PYLORI | 2004 |
|
RU2278682C2 |
METHOD OF TREATING Helicobacter pylori ASSOCIATED CHRONIC ULCEROUS DISEASE OF STOMACH AND DUODENUM | 2010 |
|
RU2416408C1 |
METHOD FOR TREATING HELICOBACTER-ASSOCIATED CHRONIC DUODENAL ULCER | 2003 |
|
RU2252777C2 |
METHOD FOR TREATING INFLAMMATORY DEGENERATIVE STOMACH AND DUODENUM DISEASES | 2005 |
|
RU2289448C1 |
METHOD FOR TREATING ULCEROUS GASTRIC AND DUODENAL DISEASE | 1999 |
|
RU2189215C2 |
Authors
Dates
2006-06-20—Published
2005-02-14—Filed